Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression
Isoliquiritigenin (ISL) is a flavonoid isolated mainly from the licorice plant, a traditional Chinese herb. ISL has shown anticancer, anti-inflammatory, antioxidant, and antidiabetic activities. However, the pharmaceutical effects of ISL on atherosclerosis are seldom explored. In this study, we used...
Saved in:
Main Authors: | Jie Qi, Jianguo Cui, Baobin Mi, Xiaohong Yan, Wenwen Xu, Hui Ma, Qingtan Zhang, Fang Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Cardiovascular Therapeutics |
Online Access: | http://dx.doi.org/10.1155/2020/1926249 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Klotho Ameliorates Podocyte Injury through Targeting TRPC6 Channel in Diabetic Nephropathy
by: Xingmei Yao, et al.
Published: (2022-01-01) -
Network pharmacology and experimental verification to investigate the mechanism of isoliquiritigenin for the treatment of Alzheimer’s disease
by: Waimao Gao, et al.
Published: (2025-02-01) -
Microglia TRPC1 SUMOylation drives neuroinflammation after stroke by modulating NLRP3 activity via increasing TRPC1 interaction with ARRB2
by: Huinan Zhang, et al.
Published: (2025-03-01) -
Role of Transient Receptor Potential Canonical Channel 6 (TRPC6) in Diabetic Kidney Disease by Regulating Podocyte Actin Cytoskeleton Rearrangement
by: Qian Wang, et al.
Published: (2020-01-01) -
Tacrolimus Protects Podocytes from Apoptosis via Downregulation of TRPC6 in Diabetic Nephropathy
by: Ruixia Ma, et al.
Published: (2021-01-01)